osteoporosis – Medxy AI

Optimizing Anabolic Therapy: A Comparative Analysis of 3-Month vs. 12-Month Romosozumab Regimens in Postmenopausal Osteoporosis

By MedXY 03/10/2026

This review analyzes the LIDA trial findings, demonstrating that an abbreviated 3-month romosozumab course followed by denosumab is non-inferior to the standard 12-month regimen in increasing total hip bone mineral density, potentially reducing costs and treatment burden.

Clinical Updates news OB/GYN & Women's Health Orthopedics

Abbreviated Romosozumab Regimens in Postmenopausal Osteoporosis: A Review of the LIDA Trial and the Shift Toward Precision Anabolic Dosing

By MedXY 03/09/2026

This review evaluates the LIDA trial's findings that 3 months of romosozumab followed by denosumab is non-inferior to 12 months of romosozumab, offering a cost-effective strategy to mitigate long-term side effects.

Diabetes & Endocrinology news Rheumatology

Short-Course Romosozumab Followed by Denosumab Is Non-Inferior to Standard 12-Month Regimen for Postmenopausal Osteoporosis

By MedXY 02/24/2026

The LIDA trial demonstrates that a 3-month abbreviated course of romosozumab followed by denosumab is non-inferior to the standard 12-month regimen in increasing total hip bone mineral density, potentially reducing treatment costs and injection burden for high-risk postmenopausal women.

Nephrology news Rheumatology

Evaluating Dapagliflozin’s Impact on Bone Health in Lupus Nephritis: Insights from a Double-Blind, Placebo-Controlled Trial

By MedXY 10/30/2025

This RCT shows dapagliflozin does not significantly affect bone metabolism or mineral density in lupus nephritis patients over 12 months, alleviating concerns about SGLT2 inhibitors' bone safety in this population.

Clinical Updates news Nursing & care Orthopedics Specialties

Revolutionizing Osteoporosis Screening in High-Risk Older Men: The Impact of a Remote Bone Health Service

By MedXY 09/02/2025

A cluster randomized trial demonstrates a centralized remote bone health service significantly improves osteoporosis screening, treatment initiation, adherence, and bone density outcomes in high-risk older men compared to usual care.

Family Medicine & Nutrition news Nursing & care Orthopedics Specialties

Nurse-Led Targeted Osteoporosis Screening Enhances Bone Health in At-Risk Older Men: Insights from a Veterans Affairs Cluster Randomized Trial

By MedXY 09/02/2025

A Veterans Affairs study demonstrates that a centralized nurse-led program markedly improves osteoporosis screening, treatment initiation, and adherence in men aged 65-85, leading to better bone density and potential reduction in fracture risk.

Clinical Updates news

Vitamin D Deficiency and Accelerated Bone Loss in Mild to Moderate COPD: New Insights from the Multi-Ethnic Study of Atherosclerosis

By MedXY 08/06/2025

Mild to moderate COPD accelerates vertebral bone mineral density loss only in individuals with vitamin D deficiency, highlighting a modifiable risk factor for osteoporosis in this population.